<DOC>
	<DOC>NCT01820481</DOC>
	<brief_summary>This clinical trial is designed to evaluate the efficacy, dose-response and safety of WIN-901X in Asthma patients.</brief_summary>
	<brief_title>Safety and Efficacy of WIN-901X in Asthma</brief_title>
	<detailed_description>Double blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>Greater than or equal to 20 and less than 80 years of age Have physician diagnosed asthma with irreversible airway obstruction at least 6 months prior to the screening FEV1 between 60% and 85% before inhaling fastacting bronchodilator at screening No history of smoking at least one year prior to the screening Having voluntarily signed an informed consent Have visited emergency room due to the worsening asthma symptoms, within 4 weeks before the screening Have been hospitalized due to an acute worsening of asthma within 3 months before the screening Have a history of laryngitis, pyrexia, sinusitis, otitis media, respiratory tract infection, and infectious rhinitis within 4 weeks prior to the screening Have malignant tumor</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Asthma</keyword>
	<keyword>Bronchial Diseases</keyword>
	<keyword>Respiratory Tract Diseases</keyword>
	<keyword>Lung Diseases, Obstructive</keyword>
	<keyword>Lung Diseases</keyword>
</DOC>